January 5, 2017 / 1:32 PM / a year ago

BUZZ-U.S. STOCKS ON THE MOVE-CEB, Pieris Pharma, Halozyme, Aeterna

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, here ; for the Morning News Call newsletter, here ) U.S. stock index futures were down on Thursday.

Dow Jones industrial average futures were down 0.08 percent at 19,840, S&P 500 futures were down 0.17 percent at 2,260.5 and Nasdaq 100 futures were down 0.16 percent at 4,925.5.

** MACY‘S INC, Wednesday close $35.84, -10.21 pct premarket

** KOHL‘S CORP, Wednesday close $51.88, -13.84 pct premarket

The department store chains cut their 2016 profit forecasts, after holiday season sales fell more than expected.

** CTI BIOPHARMA CORP, Wednesday close $3.97, +24.69 pct premarket

The drug developer said the U.S. FDA has removed full clinical hold on its experimental blood cancer drug, pacritinib.

** CEB INC, Wednesday close $61.9, +22.78 pct premarket

IT research and advisory company Gartner Inc said it would buy CEB, a provider of business research and analysis, in a cash-and-stock deal valued at $2.6 billion to expand its business globally.

** PIERIS PHARMACEUTICALS, Wednesday close $1.4699, +28.58 pct premarket

The company announced a collaboration in immunology with France-based Servier.

** HALOZYME THERAPEUTICS INC, Wednesday close $10.69, +23.48 pct premarket

Halozyme said its flagship drug delivery technology in tandem with therapies from Celgene Corp and Eli Lilly and Co succeeded in a mid-stage study involving patients with an advanced form of pancreatic cancer.

** ALEXION PHARMACEUTICALS INC, Wednesday close $127.11, +5.15 pct premarket

The drugmaker see no need to restate previously issued results, following an investigation related to sales practices of its blood disorder drug, Soliris.

** CESCA THERAPEUTICS INC, Wednesday close $3.67, +18.26 pct premarket

The company announced FDA approval of IDE supplement for Phase III clinical trial.

** AETERNA ZENTARIS INC, Wednesday close $3.65, -31.78 pct premarket

The Canadian drug developer’s experimental test to diagnose adult growth hormone deficiency (AGHD) failed late-stage study.

** HERON THERAPEUTICS INC, Wednesday close $13.8, -9.46 pct premarket

Heron on Wednesday said its experimental combination drug for post-operative pain led to significant reductions in pain intensity and the need for opioids, according to initial data from a mid-stage trial.

At least two brokerages cut their price targets on the stock.

** AMAZON.COM INC, Wednesday close $757.18, -0.21 pct premarket

The online retailer and teen apparel store chain Forever 21 Inc are among the companies weighing offers to acquire bankrupt American Apparel LLC, people familiar with the talks said on Wednesday. (Compiled by Rishika Sadam in Bengaluru; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below